A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus
Latest Information Update: 18 Jan 2023
Price :
$35 *
At a glance
- Drugs Riboflavin (Primary)
- Indications Keratoconus
- Focus Therapeutic Use
- Acronyms EVOKE
- 12 Jan 2023 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 10 to 216. Masking will be Double blind now instead of Open Label. Primary endpoint and number of arms are also changed, Randomization will be done.
- 12 Jan 2023 Planned number of patients changed from 10 to 216.
- 12 Jan 2023 Planned End Date changed from 1 Jan 2024 to 30 Nov 2028.